abatacept
bms
[]
18mo data of ariaa study (6mo aba in pre-ra):
12mo after discontinuation
progression to ra aba 35% vs pbo 57% p=0.008
improvement in synovitis, osteitis &amp; tenosynovitis aba 57% vs. 29% pbo
enough to move into clinical application? abs#0530 #acr22 
MD, PhD Institute of Infection and Immunity @UofGlasgow UK. Past Co-chair of @EULAR Synovitis Study Group. CrossFit athlete and Mountains lover. Views my own.